LVTX LAVA Therapeutics
- 1.110
- -0.090-7.50%
- 1.140
- +0.030+2.70%
LAVA Therapeutics News
Leerink Partners Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating, Announces Target Price $2
Hold Rating on LAVA Therapeutics Amid Uncertainty and Program Discontinuation
Express News | LAVA Therapeutics NV : Leerink Partners Cuts to Market Perform From Outperform
JMP Securities Downgrades LAVA Therapeutics to Market Perform, Maintains Price Target to $6
LAVA Therapeutics Analyst Ratings
JMP Securities Downgrades LAVA Therapeutics(LVTX.US) to Hold Rating
LAVA Therapeutics Reports Increased Losses Amid Declining Revenues
LAVA Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
LAVA Therapeutics Ends LAVA-1207 Program And Reprioritizes Pipeline
LAVA Therapeutics GAAP EPS of -$0.46 Misses by $0.13
Lava Therapeutics Cash Runway Extended Into 2027, Based on a Cash Balance of $78.9M, as of Sept 30 >LVTX
Express News | LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension Into 2027
Lava Therapeutics 3Q Loss/Shr 46c >LVTX
Lava Therapeutics 3Q Loss $12.3M >LVTX
Press Release: LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension Into 2027
Kling Biotherapeutics Strengthens Leadership Team to Advance Pipeline Using Its Proprietary Primary B-Cell Selection and Evolution Platform
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Jefferies Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Jefferies analyst Roger Song maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 30.1% and a
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy Rating
Buy Rating Affirmed: LAVA Therapeutics' Financial Stability and Promising Clinical Pipeline
No Data